Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating

Investing.com

Published Jul 09, 2025 07:25AM ET

Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating

Investing.com - Wedbush initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with an Outperform rating and a price target of $38.00 on Wednesday. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $16 to $42.

The research firm highlighted RNAC as a clinical-stage biopharmaceutical company developing mRNA cell therapies for immunology and inflammation with significant advantages over standard DNA-based CAR-T cell therapies.

Wedbush noted these advantages include no need for conditioning with lymphodepletion, lower COGS, improved safety, and redosing potential for the company's therapies.

The firm pointed to Cartesian's lead candidate Descartes-08, a BCMA directed product that showed deeper responses in a Phase 2 myasthenia gravis trial than benchmarks for approved biologics, with a registrational Phase 3 trial (AURORA) now enrolling.

Wedbush also identified potential upside from expansion into other autoimmune indications, including a Phase 2 lupus trial with initial data expected in the second half of 2025 and an ongoing Phase 2 pediatric basket trial across multiple indications.

In other recent news, Cartesian Therapeutics has been actively engaging in several significant developments. The company recently held its 2025 Annual Meeting of Stockholders, where key decisions were made, including the election of three Class III Directors and the approval of executive compensation. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Cartesian Therapeutics also announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, a therapy for myasthenia gravis, marking a crucial milestone in its clinical trials. Analysts from H.C. Wainwright and BTIG have maintained their Buy ratings on Cartesian Therapeutics, with price targets of $40 and $42, respectively, underscoring the potential of Descartes-08. Furthermore, the company disclosed the transition of its Chief Technology Officer, Dr. Metin Kurtoglu, to a consulting role, effective May 1, 2025, with comprehensive agreements in place regarding his departure. These developments reflect Cartesian Therapeutics' ongoing strategic initiatives and progress in its therapeutic pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes